Sol-Gel (SLGL) falls 6.42% to Close at $7.94 on January 14

Equities Staff  |

Sol-Gel Technologies Ltd (NASDAQ: SLGL) shares fell 6.42%, or $0.51 per share, to close Friday at $7.94. After opening the day at $7.61, shares of Sol-Gel fluctuated between $7.76 and $7.43. 8,709 shares traded hands a decrease from their 30 day average of 41,246. Friday's activity brought Sol-Gel’s market cap to $171,100,016.

Sol-Gel is headquartered in 7 Golda Meir, Ness Ziona..

About Sol-Gel Technologies Ltd

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.

Visit Sol-Gel Technologies Ltd’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Sol-Gel Technologies Ltd and to follow the company’s latest updates, you can visit the company’s profile page here: Sol-Gel Technologies Ltd’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

Algoma Steel Upgrades Power Plant in Transition to Green Steelmaking
Insulet Gets FDA Clearance for Omnipod 5 Automated Insulin Delivery System
Russell 2000 Enters Bear Market Territory for First Time in Nearly Two Years
TG Therapeutics Tumbles 40% on Partial Clinical Trial Hold
Huawei Says Carrier Business Stable as Revenues Decline: Jeff Kagan
Time To Reconsider Galapagos as New CEO Paul Stoffels Named
Global Politics Could Drive Extreme Market Volatility in 2022
Stock Stage Sharp Monday Afternoon Rally To Erase Morning Losses

Market Movers

Sponsored Financial Content